News
PRNAD
0.0009
NaN%
--
Alterity Investors Approve Resolutions, Clearing Path Toward Pivotal MSA Trial
TipRanks · 5d ago
Alterity Therapeutics Data Presentations Support Advancement of ATH434 into Phase 3 in Multiple System Atrophy
Barchart · 05/19 06:25
Alterity Therapeutics publishes quantitative susceptibility mapping MRI data
TipRanks · 05/11 12:01
Alterity Therapeutics to Deliver Presentations at Multiple Medical Conferences in May 2026
Barchart · 05/07 06:25
Alterity Therapeutics Showcases MSA Program Ahead of Phase 3 Push
TipRanks · 05/07 01:42
Alterity Therapeutics Releases Appendix 4C – Q3 FY26 Quarterly Cash Flow Report & Corporate Update
Barchart · 04/30 06:25
Alterity advances ATH434 toward Phase 3 in Multiple System Atrophy after FDA backing
TipRanks · 04/30 01:43
Analysts Offer Insights on Healthcare Companies: PROCEPT BioRobotics (PRCT) and Alterity Therapeutics (OtherPRNAF)
TipRanks · 04/30 00:00
Alterity Therapeutics Sets Virtual General Meeting for May 29, 2026
TipRanks · 04/29 03:07
Alterity Therapeutics receives FDA feedback after second ATH434 Type C meeting
TipRanks · 04/27 11:42
Alterity Therapeutics Receives Positive FDA Feedback Following Second Type C Meeting on ATH434 Phase 3 Program in Multiple System Atrophy
Barchart · 04/27 06:25
Alterity Wins FDA Backing on CMC Plan for ATH434 Phase 3 in Multiple System Atrophy
TipRanks · 04/26 23:16
Alterity Therapeutics presents new data analyses from ATH434 trial
TipRanks · 04/22 11:44
Alterity’s ATH434 Shows Phase 2 Efficacy Signal in MSA on New Composite Scale
TipRanks · 04/22 00:08
Alterity Therapeutics Names Ann Cunningham to Board With No Initial Shareholding
TipRanks · 04/21 00:58
Alterity Therapeutics Grants 27 Million Unlisted Options Under Incentive Scheme
TipRanks · 04/20 09:15
Alterity Therapeutics Issues 212 Million Unlisted Options Under Employee Incentive Plan
TipRanks · 04/20 09:14
Alterity Therapeutics appoints Cunningham to Board of Directors
TipRanks · 04/17 11:39
Alterity Therapeutics Adds Veteran Biotech Executive Ann Cunningham to Board
TipRanks · 04/17 00:09
Alterity to Spotlight ATH434 MSA Data in Late-Breaker at AAN Meeting
TipRanks · 04/16 02:42
More
Webull provides a variety of real-time PRNAD stock news. You can receive the latest news about Alterity Therapeutics Ltd through multiple platforms. This information may help you make smarter investment decisions.
About PRNAD
Alterity Therapeutics Limited is an Australia-based clinical-stage biotechnology company. The Company is focused on developing disease modifying treatments for neurodegenerative diseases. The Company's lead asset, ATH434, is to treat various Parkinsonian disorders. ATH434 is an oral agent designed to inhibit the aggregation of pathological proteins implicated in neurodegeneration. It has the potential to treat Parkinson's disease, as well as various Parkinsonian disorders, such as Multiple System Atrophy (MSA). The Company also has a drug discovery platform generating patentable chemical compounds to intercede in disease processes. Its lead asset, ATH434, is in a randomized, double blind, placebo-controlled Phase II clinical trial in participants with MSA. The Company is also conducting various nonclinical studies with ATH434 for use in Parkinson’s disease based on imaging of brain iron, preservation of neurons, and improvements in motor performance.